Latest Insider Transactions at G1 Therapeutics, Inc. (GTHX)
This section provides a real-time view of insider transactions for G1 Therapeutics, Inc. (GTHX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of G1 Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of G1 Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 01
2022
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.93%
|
$0
$0.3 P/Share
|
Feb 01
2022
|
Jennifer K. Moses CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,333
+2.97%
|
$6,999
$3.95 P/Share
|
Jan 05
2022
|
Mark Avagliano Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,445
-6.28%
|
$14,450
$10.61 P/Share
|
Jan 05
2022
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,445
-2.21%
|
$14,450
$10.61 P/Share
|
Jan 05
2022
|
Jennifer K. Moses CFO |
SELL
Open market or private sale
|
Direct |
1,445
-3.91%
|
$14,450
$10.61 P/Share
|
Jan 05
2022
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,445
-6.28%
|
$14,450
$10.61 P/Share
|
Jan 05
2022
|
James S. Hanson General Counsel |
SELL
Open market or private sale
|
Direct |
1,445
-5.35%
|
$14,450
$10.61 P/Share
|
Jan 03
2022
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
34,125
-12.77%
|
$341,250
$10.41 P/Share
|
Jan 03
2022
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
46,000
+14.68%
|
-
|
Jan 03
2022
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+34.29%
|
-
|
Jan 03
2022
|
Rajesh Malik Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+15.52%
|
-
|
Jan 03
2022
|
Jennifer K. Moses CFO |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+24.49%
|
-
|
Jan 03
2022
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+34.29%
|
-
|
Jan 03
2022
|
Andrew Perry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+49.92%
|
-
|
Jan 03
2022
|
James S. Hanson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+30.77%
|
-
|
Nov 09
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+28.37%
|
$0
$0.39 P/Share
|
Jul 15
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-14.08%
|
$180,000
$18.49 P/Share
|
Jul 15
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.35%
|
$0
$0.39 P/Share
|
Jul 14
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-14.08%
|
$190,000
$19.08 P/Share
|
Jul 14
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.35%
|
$0
$0.39 P/Share
|
Jul 13
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-14.08%
|
$190,000
$19.45 P/Share
|
Jul 13
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.35%
|
$0
$0.39 P/Share
|
Jun 29
2021
|
Seth Rudnick |
SELL
Open market or private sale
|
Direct |
10,000
-69.5%
|
$220,000
$22.35 P/Share
|
Jun 29
2021
|
Seth Rudnick |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+25.79%
|
$0
$0.35 P/Share
|
Jun 17
2021
|
Willie A Deese |
BUY
Grant, award, or other acquisition
|
Direct |
4,389
+50.0%
|
-
|
Jun 17
2021
|
Glenn P Muir |
BUY
Grant, award, or other acquisition
|
Direct |
4,389
+2.44%
|
-
|
Jun 17
2021
|
Garry A Nicholson |
BUY
Grant, award, or other acquisition
|
Direct |
4,389
+50.0%
|
-
|
Jun 17
2021
|
Seth Rudnick |
BUY
Grant, award, or other acquisition
|
Direct |
4,389
+50.0%
|
-
|
Jun 17
2021
|
Cynthia Schwalm |
BUY
Grant, award, or other acquisition
|
Direct |
4,389
+42.7%
|
-
|
Jun 17
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-14.08%
|
$210,000
$21.77 P/Share
|
Jun 17
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.35%
|
$0
$0.39 P/Share
|
Jun 16
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-14.08%
|
$210,000
$21.74 P/Share
|
Jun 16
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.35%
|
$0
$0.39 P/Share
|
Jun 15
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-14.08%
|
$220,000
$22.39 P/Share
|
Jun 15
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.35%
|
$0
$0.39 P/Share
|
May 25
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+24.69%
|
$0
$0.39 P/Share
|
May 13
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-19.61%
|
$200,000
$20.54 P/Share
|
May 13
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.39%
|
$0
$0.39 P/Share
|
May 12
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-19.61%
|
$200,000
$20.07 P/Share
|
May 12
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.39%
|
$0
$0.39 P/Share
|
May 11
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-19.61%
|
$190,000
$19.1 P/Share
|
May 11
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.39%
|
$0
$0.39 P/Share
|
May 10
2021
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+15.8%
|
$0
$0.3 P/Share
|
Apr 22
2021
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-25.73%
|
$330,000
$22.07 P/Share
|
Apr 22
2021
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+20.46%
|
$0
$0.39 P/Share
|
Apr 15
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-19.61%
|
$240,000
$24.96 P/Share
|
Apr 15
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.39%
|
$0
$0.39 P/Share
|
Apr 14
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-19.61%
|
$240,000
$24.53 P/Share
|
Apr 14
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.39%
|
$0
$0.39 P/Share
|
Apr 13
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-19.61%
|
$230,000
$23.89 P/Share
|